Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors

Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft

(2017) Nataly Tarasenko et al.   INVESTIGATIONAL NEW DRUGS

Changes in cardiac Nav1.5 expression, function, and acetylation by pan-histone deacetylase inhibitors

(2016) Qin Xu et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Inhibitors of histone deacetylase as antitumor agents: A critical review

(2016) Mohammed Manal et al.   BIOORGANIC CHEMISTRY

Biomarkers of Response and Resistance to DNA Repair Targeted Therapies

(2016) E. H. Stover et al.   CLINICAL CANCER RESEARCH

Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma

(2016) Caroline Happold et al.   JOURNAL OF CLINICAL ONCOLOGY

Valproate in Adjuvant Glioblastoma Treatment

(2016) Michael F. Fay et al.   JOURNAL OF CLINICAL ONCOLOGY

Valproic Acid May Be Tested in Patients With H3F3A-Mutated High-Grade Gliomas

(2016) Francisco Felix et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma

(2015) Andra V. Krauze et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents

(2015) Madhusoodanan Mottamal et al.   MOLECULES

The balance of powers: Redox regulation of fibrogenic pathways in kidney injury

(2015) Daryl M. Okamura et al.   Redox Biology

A novel valproic acid prodrug as an anticancer agent that enhances doxorubicin anticancer activity and protects normal cells against its toxicity in vitro and in vivo

(2014) Nataly Tarasenko et al.   BIOCHEMICAL PHARMACOLOGY

Identification of oxidized protein hydrolase as a potential prodrug target in prostate cancer

(2014) Christopher A McGoldrick et al.   BMC CANCER

New and emerging HDAC inhibitors for cancer treatment

(2014) Alison C. West et al.   JOURNAL OF CLINICAL INVESTIGATION

Enhanced Doxorubicin Delivery to the Brain Administered Through Glutathione PEGylated Liposomal Doxorubicin (2B3-101) as Compared with Generic Caelyx,®/Doxil®—A Cerebral Open Flow Microperfusion Pilot Study

(2014) Thomas Birngruber et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Survival analysis for valproic acid use in adult glioblastoma multiforme: A meta-analysis of individual patient data and a systematic review

(2014) Yang Yuan et al.   SEIZURE-EUROPEAN JOURNAL OF EPILEPSY

Standard of Care and Promising New Agents for Triple Negative Metastatic Breast Cancer

(2014) Patrizia Mancini et al.   Cancers

Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair

(2013) B Groselj et al.   BRITISH JOURNAL OF CANCER

Evolutionary dynamics of cancer in response to targeted combination therapy

(2013) Ivana Bozic et al.   eLife

Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed

(2012) Berkley E Gryder et al.   Future Medicinal Chemistry

Disparate Impact of Butyroyloxymethyl Diethylphosphate (AN-7), a Histone Deacetylase Inhibitor, and Doxorubicin in Mice Bearing a Mammary Tumor

(2012) Nataly Tarasenko et al.   PLoS One

Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma

(2011) Karen M VanderMolen et al.   JOURNAL OF ANTIBIOTICS

Inhibition of Histone Deacetylase in Cancer Cells Slows Down Replication Forks, Activates Dormant Origins, and Induces DNA Damage

(2010) Chiara Conti et al.   CANCER RESEARCH

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity

(2010) Nataly Tarasenko et al.   INVESTIGATIONAL NEW DRUGS

Dynamic changes in histone acetylation regulate origins of DNA replication

(2010) Ashwin Unnikrishnan et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Histone deacetylases and epigenetic therapies of hematological malignancies

(2010) Ciro Mercurio et al.   PHARMACOLOGICAL RESEARCH

Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC

(2009) P. Munster et al.   CLINICAL CANCER RESEARCH

Clinical Studies of Histone Deacetylase Inhibitors

(2009) H. M. Prince et al.   CLINICAL CANCER RESEARCH

Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions

(2009) C. Choudhary et al.   SCIENCE

HDAC expression and clinical prognosis in human malignancies

(2008) Wilko Weichert   CANCER LETTERS

Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex)

(2008) Nataly Tarasenko et al.   CLINICAL & EXPERIMENTAL METASTASIS

 -H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin

(2008) A. Kinner et al.   NUCLEIC ACIDS RESEARCH

Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RARα

(2007) Oliver H. Krämer et al.   FASEB JOURNAL